INM - InMed Pharmaceuticals Inc.
3.13
0.030 0.958%
Share volume: 43,000
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.24%
PREVIOUS CLOSE
CHG
CHG%
$3.10
0.06
0.02%
Fundamental analysis
29%
Profitability
0%
Dept financing
14%
Liquidity
75%
Performance
50%
Performance
5 Days
1.62%
1 Month
-37.02%
3 Months
1,291.11%
6 Months
2,206.56%
1 Year
878.13%
2 Year
46.26%
Key data
Stock price
$3.13
DAY RANGE
$2.95 - $3.19
52 WEEK RANGE
$0.12 - $8.27
52 WEEK CHANGE
$878.74
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Eric A. Adams
Region: US
Website: inmedpharma.com
Employees: 10
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: inmedpharma.com
Employees: 10
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
InMed Pharmaceuticals Inc. researches and develops cannabinoid-based therapies. Lead product INM-755, a cannabinoidol topical cream, is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing InM-088, which is in preclinical studies for the. treatment of glaucoma and pain.
Recent news